CN106456572A - 用于增加mhc‑i表达的姜黄根醇化合物 - Google Patents

用于增加mhc‑i表达的姜黄根醇化合物 Download PDF

Info

Publication number
CN106456572A
CN106456572A CN201480072728.3A CN201480072728A CN106456572A CN 106456572 A CN106456572 A CN 106456572A CN 201480072728 A CN201480072728 A CN 201480072728A CN 106456572 A CN106456572 A CN 106456572A
Authority
CN
China
Prior art keywords
cell
monoclonal antibody
cancer
melanoma
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480072728.3A
Other languages
English (en)
Chinese (zh)
Inventor
威尔弗雷德·A·杰弗里斯
瑞恩哈德·加巴斯勒尔
雷蒙德·安德森
莉莉安·野原
大卫·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alternative Extract Co
JEFFERIES WILFRED A.
Lilian Dhidhi
Raymond Anderson
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN106456572A publication Critical patent/CN106456572A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201480072728.3A 2013-11-20 2014-11-20 用于增加mhc‑i表达的姜黄根醇化合物 Pending CN106456572A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361906817P 2013-11-20 2013-11-20
US61/906,817 2013-11-20
PCT/US2014/066543 WO2015077411A1 (en) 2013-11-20 2014-11-20 Curcuphenol compounds for increasing mhc-i expression

Publications (1)

Publication Number Publication Date
CN106456572A true CN106456572A (zh) 2017-02-22

Family

ID=52117996

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480072728.3A Pending CN106456572A (zh) 2013-11-20 2014-11-20 用于增加mhc‑i表达的姜黄根醇化合物

Country Status (10)

Country Link
US (4) US20150147314A1 (https=)
EP (2) EP3071192B1 (https=)
JP (4) JP6560215B2 (https=)
CN (1) CN106456572A (https=)
CA (1) CA2930156C (https=)
DK (1) DK3071192T3 (https=)
ES (1) ES2775577T3 (https=)
HU (1) HUE049301T2 (https=)
PL (1) PL3071192T3 (https=)
WO (1) WO2015077411A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930156C (en) 2013-11-20 2023-11-07 Biommune Technologies Inc. Curcuphenol compounds for increasing mhc-i expression
EP3324967A4 (en) * 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
JP7520013B2 (ja) * 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
WO2020154811A1 (en) 2019-01-31 2020-08-06 Cava Healthcare Inc. Compounds for increasing mhc-i expression and modulating histone deacetylase activity
WO2022125339A2 (en) * 2020-12-07 2022-06-16 The Trustees Of Indiana University Methods to sensitize cancer cells to immune attack using atractylenolide i

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261939A (ja) * 1985-09-10 1987-03-18 Yamanouchi Pharmaceut Co Ltd クルクフエノ−ル誘導体及びこれを含有する医薬
CN1527703A (zh) * 2001-03-22 2004-09-08 Ŀ� 预防和治疗癌症及治疗炎症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100571159B1 (ko) * 2003-06-24 2006-04-18 박광균 항암제로 유발되는 독성의 억제제 및 이를 함유하는항암제 조성물
CA2688570A1 (en) * 2007-05-31 2008-12-04 F.P.L. Pharma Inc. Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof
CA2930156C (en) 2013-11-20 2023-11-07 Biommune Technologies Inc. Curcuphenol compounds for increasing mhc-i expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6261939A (ja) * 1985-09-10 1987-03-18 Yamanouchi Pharmaceut Co Ltd クルクフエノ−ル誘導体及びこれを含有する医薬
CN1527703A (zh) * 2001-03-22 2004-09-08 Ŀ� 预防和治疗癌症及治疗炎症的药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMY E. WRIGHT等: "(+)-CURCUPHENOL AND (+)-CURCUDIOL,SESQUITERPENE PHENOLS FROM SHALLOW AND DEEP WATER COLLECTIONS OF THE MARINE SPONGE DlDlSCUS FLAVUS", 《JOURNAL OF NATURAL PRODUCTS》 *
FATHY A.BEHERY等: "Mannich- and Lederer–Manasse-based analogues of the natural product S-(+)-curcuphenol as cancer proliferation and migration inhibitors", 《MED.CHEM.COMMUN》 *
JASON C. GREEN等: "An Oxidative Dearomatization-Induced [5+2] Cascade Enabling the Syntheses of α-Cedrene, α-Pipitzol,and sec-Cedrenol", 《J.AM.CHEM.SOC》 *
WASEEM GUL等: "Chemical transformation and biological studies of marine sesquiterpene (S)-(+)-curcuphenol and its analogs", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途

Also Published As

Publication number Publication date
DK3071192T3 (da) 2020-03-16
US20150147314A1 (en) 2015-05-28
EP3639815A1 (en) 2020-04-22
HUE049301T2 (hu) 2020-09-28
CA2930156A1 (en) 2015-05-28
EP3071192A1 (en) 2016-09-28
US20200375917A1 (en) 2020-12-03
CA2930156C (en) 2023-11-07
PL3071192T3 (pl) 2020-06-29
JP7071570B2 (ja) 2022-05-19
JP2021100982A (ja) 2021-07-08
US10751296B2 (en) 2020-08-25
JP2022093724A (ja) 2022-06-23
US20220062195A1 (en) 2022-03-03
WO2015077411A1 (en) 2015-05-28
JP2016539129A (ja) 2016-12-15
ES2775577T3 (es) 2020-07-27
JP6560215B2 (ja) 2019-08-14
US11197832B2 (en) 2021-12-14
US12011421B2 (en) 2024-06-18
JP2019196380A (ja) 2019-11-14
EP3071192B1 (en) 2019-12-18
US20170319508A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
JP7071570B2 (ja) Ｍｈｃ－ｉの発現を増加させるためのクルクフェノール化合物
US20260091081A1 (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
EP3102585A1 (en) Boronic acid esters and pharmaceutical formulations thereof
KR20110028454A (ko) 다발성 골수종 치료법
BR112019009799A2 (pt) método para tratar câncer em um paciente
JP6649953B2 (ja) 免疫療法による治療および組成物
ES2953032T3 (es) Métodos ex vivo para la activación de las células inmunológicas
WO2017063023A1 (en) Compositions and methods for the treatment of diseases involving mucin
CN114401736A (zh) 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm
US20110217258A1 (en) Combined Use of Bendamustine, Doxorubicin and Bortezomib for the Treatment of Multiple Myeloma
WO2022182993A1 (en) Liposomal formulations of boronic acid containing active agents
EP4529457A1 (en) Method for pretreating relapsing cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: British Columbia

Applicant after: Pascal Biosciences

Address before: British Columbia

Applicant before: JEFFERIES, Wilfred

Address after: British Columbia

Applicant after: Kava health care

Address before: British Columbia

Applicant before: Alternative extract Co.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200114

Address after: British Columbia

Applicant after: Alternative extract Co.

Address before: British Columbia

Applicant before: JEFFERIES WILFRED A.

Applicant before: Raymond Anderson

Applicant before: Lilian Dhidhi

Effective date of registration: 20200114

Address after: British Columbia

Applicant after: JEFFERIES WILFRED A.

Applicant after: Raymond Anderson

Applicant after: Lilian Dhidhi

Address before: British Columbia

Applicant before: THE University OF BRITISH COLUMBIA

Effective date of registration: 20200114

Address after: British Columbia

Applicant after: THE University OF BRITISH COLUMBIA

Address before: British Columbia

Applicant before: JEFFERIES WILFRED A.

Effective date of registration: 20200114

Address after: British Columbia

Applicant after: JEFFERIES WILFRED A.

Address before: British Columbia

Applicant before: Pascal Biosciences

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222